HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Active:	Yes
Cancer Type:	Cancer-Related Syndrome Leukemia Lymphoma Myelodysplastic Syndromes (MDS)	NCT ID:	NCT04904588
Trial Phases:	Phase II	Protocol IDs:	ACCESS (primary) NCI-2021-06605
Eligibility:	1 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Center for International Blood and Marrow Transplant Research
NCI Full Details:	http://clinicaltrials.gov/show/NCT04904588

Summary

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation
(HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral
blood stem cell transplant in adults and bone marrow stem cell transplant in children.
Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be
used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well
this treatment works in patients with hematologic malignancies.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.